Full Archive
Primary Outcome Measures Progression free survival [ Time Frame: From randomisation up to 2 years of follow up ] Defined as the time from randomisation to the date of disease progression Overall survival [ Time Frame: From randomisation up to 2 years of follow up ] defined as the time from randomisation to the date of death from any cause. Secondary Outcome Measures…
It is best to treat peritoneal mesothelioma as soon as possible. Waiting to receive treatment could prevent a patient from living longer than possible. Information from a study looking at treatment start times was published in the Journal of Gastrointestinal Surgery in November. Researchers observed patients who either received treatment quickly, had a delay in…
Primary Outcome Measures Maximum Tolerated Dose (MTD) and/or Maximum Administered Dose (MAD) [ Time Frame: 28 days during 1st cycle ] Determine the MTD and/or MAD of anti GP88 monoclonal antibody (AG-01) in subjects with advanced/refractory solid tumor malignancies for which no effective therapies exist. Antitumor Activity of AG-01 by Overall Response Rate (ORR) [ Time Frame: Every 56 Days ] To evaluate…
Mesothelioma diagnoses have almost doubled in the last 30 years, highlighting the need for better care and more ways to regulate and reduce asbestos exposure. There were around 35,000 people diagnosed with mesothelioma in 2019, while in 1990 there were around 19,000 people diagnosed. This information was released by the Clinical Research Center at Shandong…
The most aggressive surgery for mesothelioma could be more beneficial for patients with the disease. The more aggressive surgery is called an extrapleural pneumonectomy (EPP), which involves removing the lung. The other surgery, pleurectomy and decortication (P/D), spares the lung and only removes the lining of the lung and visible tumors. A study from Italy…
A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of Opdivo and Yervoy. The combination…
When people are diagnosed with mesothelioma, it is common for the disease to spread. This occurs in around 60 percent of people, but it does not usually spread to the brain. Researchers in Great Britain believe doctors should be focusing on cerebral metastasis in mesothelioma patients in addition to other areas of the body because…
Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso, ADI-PEG 20 showed effectiveness when used for sarcomatoid and biphasic mesothelioma, the two most resistive to treatment. The enzyme is able to limit an amino…
Primary Outcome Measures Number of participants with adverse events (AEs) [ Time Frame: Through 30 days after the last study treatment; approximately 7 months ] Any untoward medical occurrence in a clinical investigational participant administered a medicinal product and which does not necessarily have a causal relationship with this treatment. Number of participants with laboratory abnormalities [ Time Frame: Through 30 days…
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for solid tumors (including mesothelioma) that…
